-Jingrui Jiang Researcher Activity Profile

Research Author Detailed Information 

Jingrui Jiang Publication Rate By Year

Jingrui Jiang has published 1 paper(s) in 2006, 7 paper(s) in 2007, 2 paper(s) in 2008, for a total of 10 research publications in total.

Jingrui J Jiang Author Information

LAST NAME: jiang

FIRST NAME: jingrui

INITIALS: J

AFFILIATION:

Papers

Jingrui Jiang's Publication Record

1. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
2. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Year Published: 2007
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
3. Allele-Dependent Variation in the Relative Cellular Potency of Distinct EGFR Inhibitors. Year Published: 2007
Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
4. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
5. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Year Published: 2007
Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
6. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
7. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
8. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Year Published: 2007
Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
9. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
10. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.